Schwab Charles Investment Management Inc. grew its stake in MEDNAX Inc (NYSE:MD) by 7.1% during the second quarter, according to its most recent 13F filing with the SEC. The firm owned 390,747 shares of the company’s stock after acquiring an additional 26,064 shares during the period. Schwab Charles Investment Management Inc.’s holdings in MEDNAX were worth $16,912,000 as of its most recent filing with the SEC.

Several other institutional investors also recently added to or reduced their stakes in the company. Fort Washington Investment Advisors Inc. OH increased its stake in MEDNAX by 55.7% during the 2nd quarter. Fort Washington Investment Advisors Inc. OH now owns 363,201 shares of the company’s stock worth $15,719,000 after buying an additional 130,001 shares during the period. Bank of Montreal Can increased its stake in MEDNAX by 6.8% during the 2nd quarter. Bank of Montreal Can now owns 210,277 shares of the company’s stock worth $9,102,000 after buying an additional 13,360 shares during the period. Legal & General Group Plc increased its stake in MEDNAX by 16.4% during the 1st quarter. Legal & General Group Plc now owns 137,616 shares of the company’s stock worth $7,655,000 after buying an additional 19,421 shares during the period. Pzena Investment Management LLC increased its stake in MEDNAX by 1.8% during the 2nd quarter. Pzena Investment Management LLC now owns 2,299,800 shares of the company’s stock worth $99,535,000 after buying an additional 41,088 shares during the period. Finally, State of Alaska Department of Revenue increased its stake in MEDNAX by 40.1% during the 2nd quarter. State of Alaska Department of Revenue now owns 10,030 shares of the company’s stock worth $434,000 after buying an additional 2,870 shares during the period. 95.51% of the stock is currently owned by institutional investors and hedge funds.

In other news, insider John C. Pepia sold 3,500 shares of the company’s stock in a transaction on Tuesday, August 14th. The shares were sold at an average price of $48.18, for a total value of $168,630.00. Following the completion of the transaction, the insider now owns 30,148 shares in the company, valued at approximately $1,452,530.64. The sale was disclosed in a document filed with the SEC, which is available at this link. Corporate insiders own 2.40% of the company’s stock.

Shares of MEDNAX stock opened at $47.68 on Friday. MEDNAX Inc has a 12-month low of $40.56 and a 12-month high of $63.04. The company has a quick ratio of 1.52, a current ratio of 1.52 and a debt-to-equity ratio of 0.59. The firm has a market capitalization of $4.48 billion, a PE ratio of 13.92, a P/E/G ratio of 1.30 and a beta of 0.24.

MEDNAX (NYSE:MD) last issued its earnings results on Thursday, August 2nd. The company reported $1.07 earnings per share (EPS) for the quarter, meeting the consensus estimate of $1.07. MEDNAX had a net margin of 9.59% and a return on equity of 10.42%. The business had revenue of $915.90 million during the quarter, compared to analysts’ expectations of $911.77 million. During the same quarter in the prior year, the business posted $0.85 EPS. The company’s revenue for the quarter was up 8.6% on a year-over-year basis. research analysts expect that MEDNAX Inc will post 3.67 earnings per share for the current year.

A number of brokerages have commented on MD. Zacks Investment Research raised shares of MEDNAX from a “sell” rating to a “hold” rating in a research report on Tuesday, August 7th. ValuEngine raised shares of MEDNAX from a “strong sell” rating to a “sell” rating in a research report on Friday, August 3rd. Stifel Nicolaus set a $47.00 price objective on shares of MEDNAX and gave the company a “hold” rating in a research report on Thursday, August 2nd. Credit Suisse Group raised shares of MEDNAX from a “neutral” rating to an “outperform” rating and increased their price objective for the company from $47.00 to $55.00 in a research report on Friday, August 3rd. Finally, Leerink Swann began coverage on shares of MEDNAX in a research report on Thursday, July 12th. They issued a “market perform” rating and a $50.00 price objective on the stock. One analyst has rated the stock with a sell rating, ten have issued a hold rating and four have assigned a buy rating to the stock. The company currently has a consensus rating of “Hold” and an average price target of $54.71.

About MEDNAX

MEDNAX, Inc, together with its subsidiaries, provides newborn, anesthesia, maternal-fetal, radiology, pediatric cardiology, and other pediatric subspecialties physician services in the United States and Puerto Rico. It offers neonatal care services, such as clinical care to babies born prematurely or with complications within specific units at hospitals through neonatal physician subspecialists, neonatal nurse practitioners, and other pediatric clinicians; anesthesia and anesthesia subspecialty care; and acute and chronic pain management services.

Further Reading: Diversification in Your Portfolio

Want to see what other hedge funds are holding MD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for MEDNAX Inc (NYSE:MD).

Institutional Ownership by Quarter for MEDNAX (NYSE:MD)

Receive News & Ratings for MEDNAX Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MEDNAX and related companies with MarketBeat.com's FREE daily email newsletter.